The present inventor has discovered how to adsorb a mitochondrially targeted compound (MTC) of general formula I on contact lenses and other matrices prior to the application of lenses or other matrix on the eye surface. After such matrix is positioned on the eye, MTC is translocated from the lens into cornea cells of the eye providing cornea protective effect and thus reducing side effects of contact lens application.

The invention relates to the manufacturing and use of pharmaceutical compositions of medicines (ophthalmic preparations) comprising a mitochondria-addressed antioxidant and a set of auxiliary substances providing effective treatment for ophthalmological diseases in humans and animals.

This invention relates to a compound for labeling mitochondria and a method of producing the same, wherein the compound is represented by Chemical Formula 1 or Chemical Formula 2 below, and is useful in labeling mitochondria. ##STR00001## In Chemical Formulas 1 and 2, n is 4 or 10.

The present inventor has discovered how to adsorb a mitochondrially targeted compound (MTC) of general formula I on contact lenses and other matrices prior the application of lenses or other matrix on the eye surface. After such matrix is positioned on eye, MTC is translocated from lens into cornea cells of the eye providing cornea protective effect and thus reducing side effects of contact lens application.

An anticorrosive pigment comprising an aluminum polyphosphate comprises at least one cerium-based compound and/or one lanthanum-based compound and/or one praseodymium-based compound. An anticorrosive paint incorporating the pigment is also provided.

The present invention relates to an antioxidant compound having anti atherosclerotic effect and preparation thereof. The present invention more particularly relates to the synthesis of TPP+ coupled esculetin (mitochondria-targeted esculetin [Mito-Esc]) followed by the biological evaluation of Mito-Esc for its ability to attenuate Angiotensin-II-induced atherosclerosis in apolipoproteinE knockout (ApoE.sup./ mice along with the endothelial cell age-delaying effects of Mito-Esc.

There are provided fluorogenic labelling agents comprising a dimaleimide core connected to a BODIPY-based fluorophore, processes for preparation thereof, and uses thereof for labelling and/or detection of specific protein targets. Fluorogenic labelling agents having an excitation wavelength that can be visualized in the green or red channels of fluorescence microscopes are provided. In some embodiments, fluorogenic labelling agents comprising a compound having the structure of Formula I or II, and salts thereof, are described. ##STR00001##

The subject of the invention are new mitochondrially targeted E/Z isomers of aliphatic triphenylphosphonium derivatives of tamoxifen where the aliphatic chain is alkyl or alkenyl, and their corresponding tertiary amine salts and/or their mixture (MitoTAX). Alkyl triphenylphosphonium derivatives of tamoxifen have the general formula (I), where n=8 to 12 and where Z is selected from the group of organic salts or inorganic salts. Alkenyl triphenylphosphonium derivatives of tamoxifen have the general formula IA, where n=6 to 10 and where Z has the above mentioned meaning. These compounds are applicable for the treatment of neoplastic disease, especially those with high HER2 protein levels. The drug for the treatment of neoplastic diseases according to the invention contains at least one E/Z isomer of aliphatic triphenylphosphonium derivatives of tamoxifen of the general formula (I) and/or IA or their corresponding salts of tertiary amine.

The invention relates to the manufacturing and use of pharmaceutical compositions of medicines (ophthalmic preparations) comprising a mitochondria-addressed antioxidant and a set of auxiliary substances providing effective treatment for ophtalmological diseases in humans and animals.

The present invention relates to an antioxidant compound having anti atherosclerotic effect and preparation thereof. The present invention more particularly relates to the synthesis of TPP+ coupled esculetin (mitochondria-targeted esculetin [Mito-Esc]) followed by the biological evaluation of Mito-Esc for its ability to attenuate Angiotensin-II-induced atherosclerosis in apolipoproteinE knockout (ApoE.sup./ mice along with the endothelial cell age-delaying effects of Mito-Esc.